GO
Loading...

Biotech's $10 billion opportunity

Tuesday, 2 Sep 2014 | 1:34 PM ET

CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.